Hot Products
| Catalog No. | Information |
| CFN90315 | Breviscapine Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway . |
| CFN92601 | Britannilactone Britannilactone significantly reduces melanin production in a dose-dependent manner with the IC50 value of 15.5 uM. |
| CFN90220 | Britannin Britannin has strong cytotoxicity to HepG-2, MCF-7, MDBK and A-549 cells (IC50: 2.2, 5.9, 5.4, and 3.5 microg/mL, respectively). Britannin inhibits growth of MCF-7 and MDA-MB-468 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may potentially serve as an agent for breast cancer therapy. |
| CFN92774 | Broussoflavonol B Broussoflavonol B is a potent growth inhibitor of ER-negative breast cancer stem-like cells, may be used to treat breast cancer. Broussoflavonol B increases the growth inhibitory activity of tamoxifen in tumorsphere cells derived from MCF7/TAM cells. |
| CFN92664 | Broussoflavonol F Broussoflavonol F has antiplatelet effect, is partially due to an inhibitory effect on cyclooxygenase, can inhibit arachidonic acid (AA)-induced platelet aggregation. Broussoflavonol F shows inhibitory activities on mushroom tyrosinase. Broussoflavonol F shows radical scavenging against 2,2-diphenyl-1-picrylhydrazyl (DPPH), the IC50 value of 708.54 uM. It also exhibits moderate cytotoxic activities against five human cancer cells with the IC50 value of 0.41-7.2 ug/mL. |
| CFN97694 | Broussonin A Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin A shows estrogenic activity with ligand-binding activity of estrogen receptor, transcriptional activity of estrogen-responsive element-luciferase reporter genes. Broussonin A can significantly inhibit adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay; it suppresses lipopolysaccharide (LPS)-stimulated inducible nitric oxide synthase (iNOS) expression at the transcriptional level through modulating NF-κB and down-regulation of the Akt and ERK signaling pathways. |
| CFN97695 | Broussonin B Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin B can induce neurite outgrowth in PC-12 cells at concentration of 50 microg/ml, and show moderate inhibitory activities against a chymotrypsin-like activity of the proteasome.Broussonin B also can significantly inhibit adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay. |
| CFN97474 | Broussonin E Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway, and can be further developed as a promising drug for the treatment of inflammation-related diseases such as atherosclerosis. |
| CFN89339 | Bruceantin Bruceantin has antiviral activity, it can inhibit pepper mottle virus in pepper; it also shows high antimalarial activity. Bruceantin is an effective agent in controlling the proliferation, viability and migration of multiple myeloma cancer stem cells (CSCs) as well as angiogenesis in vitro. Bruceantin exhibits NF-κB p65 inhibition, and cytotoxic potential against HT-29, HeLa, and HL-60 cells . |
| CFN89336 | Bruceantinol Bruceantinol has antiviral activity, it can inhibit pepper mottle virus in pepper; it shows antibabesial activity against Babesia gibsoni in vitro, with the IC50 value of 12 ng/mL. Bruceantinol shows in vitro inhibitory activity against Trypanosoma evansi. |
